A team headed by ICREA researcher Eduard Batlle discovers that immune system-stimulating treatments combined with a TGF-beta inhibitor are effective against colon cancer.
The researchers developed a mouse model that mimics advanced human colon cancer. This model has allowed them to study the immune system response for the first time.
A study published in Nature Communications and led by Maria J Macias highlight new DNA motifs for the Smads proteins.
A team of scientists headed by Roger Gomis at IRB Barcelona reveals one of the mechanisms that allows metastatic cells to leave a latent state.
It is a factor that has been conserved through evolution, from plants to mammals
RPAP1 regulates the activity of RNA polymerase II by means of its interaction with gene transactivators
A team headed by Antonio Zorzano at IRB Barcelona has identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes.
The protein is a key regulator of many mitochondrial functions, as well as of the cell as a whole.
Published in Nature Cell Biology (NCB), the study shows that the EXD2 protein is critical for the mitochondria, the cell’s powerhouses, to produce energy.
This protein was previously thought to be located in the cell nucleus and to be involved in DNA repair.
The results contribute to our basic understanding of mitochondria and suggest that EXD2 could be important for fertility and represent a potential target for cancer therapy.
Researchers at IRB Barcelona unravel the role of the histone BigH1 in the development of male sex cells from stem cells.
The study, which was performed in Drosophila melanogaster, paves the way to a greater understanding of male infertility.
Published in Cell Reports, the work sheds light on the mechanisms through which histones regulate how stem cells give rise to differentiated cells.
Xavier Salvatella, ICREA researcher at IRB Barcelona, proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently available.
The incidence of prostate cancer is increasing worldwide. In the US and Europe, it is one of the most common tumours and among the main causes of death by cancer.
A study published by IRB Barcelona in Nature Genetics demonstrates that the error (mutation) surveillance and repair system shows greater efficiency in the protein-coding regions of genes.
A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.